July 2018

Inhaling vaporized cannabis does not improve breathlessness or exercise endurance in patients with advanced chronic obstructive pulmonary disease (COPD), according to a small Canadian study. The study reporting the findings, “Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced COPD: A randomized controlled trial,” was published in the journal Annals of the […]

Mice with pancreatic cancer that were treated with CBD alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone… Mice with pancreatic cancer that were treated with a naturally occurring constituent of medicinal cannabis alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone, a new study reports. The […]

Zogenix, Inc.  announced successful completion of its second confirmatory phase III study (Study 1504) evaluating its pipeline candidate, ZX008 (low-dose fenfluramine hydrochloride), for treating Dravet syndrome, a type of epilepsy in children and young adults. The data was consistent with the positive results observed in the first pivotal phase III study in reducing monthly convulsive […]

For those looking for technical and financial performance in the OTC space right now, CV Sciences Inc (OTCMKTS:CVSI) is an interesting case study. Helping to confirm that sense, the company just announced unaudited second quarter 2018 revenue and selected business highlights for the quarter ended June 30, 2018. According to the release, “Second quarter 2018 […]

For those looking for technical and financial performance in the OTC space right now, CV Sciences Inc (OTCMKTS:CVSI) is an interesting case study. Helping to confirm that sense, the company just announced unaudited second quarter 2018 revenue and selected business highlights for the quarter ended June 30, 2018. According to the release, “Second quarter 2018 […]

The U.S. Food and Drug Administration on Monday approved the country’s first drug derived from marijuana, a medication that treats two rare and devastating forms of epilepsy. The drug, produced by GW Pharmaceuticals plc (Nasdaq: GWPH) and called Epidiolex®, is made from cannabidiol (CBD), a component of marijuana that does not give users a high. […]

<!– Market News –> July 24, 2018 – By Margaret Guttierez Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in July as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s […]

<!– Market News –> July 24, 2018 – By Margaret Guttierez Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in July as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s […]

Satipharm’s CBD capsules significantly reduced monthly seizure frequency in the treatment resistant children when added to current medications. Biotech and global cannabis investment company MMJ (ASX: MMJ) has published results from its phase 2 clinical trial, completed through its subsidiary PhytoTech Therapeutics. MMJ’s study indicates as many as 82% of patients noticed a reduction in […]

Image: Botanix Australia’s Botanix (ASX:BOT) has partnered with the University of Queensland’s (UQ) Institute for Molecular Bioscience (IMB) to accelerate the company’s BTX 1801 toward clinical trials. BTX 1801 is a cannabidiol-based treatment with potential to “address unmet needs” in serious skin infections. Among the activities during the collaboration will be an assessment of BTX […]